Detalhe da pesquisa
1.
Single-cell multi-omics analysis of COVID-19 patients with pre-existing autoimmune diseases shows aberrant immune responses to infection.
Eur J Immunol
; 54(1): e2350633, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-37799110
2.
Risk of secondary progressive multiple sclerosis after early worsening of disability.
J Neurol Neurosurg Psychiatry
; 94(12): 984-991, 2023 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37414538
3.
Disability accrual in primary and secondary progressive multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 94(9): 707-717, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37068931
4.
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis.
Mult Scler
; 29(7): 875-883, 2023 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-36851894
5.
Comparative effectiveness in multiple sclerosis: A methodological comparison.
Mult Scler
; 29(3): 326-332, 2023 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36800908
6.
Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis.
Eur J Neurol
; 30(4): 1014-1024, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36692895
7.
Epstein-Barr Virus and Multiple Sclerosis: A Convoluted Interaction and the Opportunity to Unravel Predictive Biomarkers.
Int J Mol Sci
; 24(8)2023 Apr 17.
Artigo
Inglês
| MEDLINE | ID: mdl-37108566
8.
Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis.
Mult Scler
; 27(5): 755-766, 2021 04.
Artigo
Inglês
| MEDLINE | ID: mdl-32538713
9.
Early clinical markers of aggressive multiple sclerosis.
Brain
; 143(5): 1400-1413, 2020 05 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32386427
10.
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 90(4): 458-468, 2019 04.
Artigo
Inglês
| MEDLINE | ID: mdl-30636699
11.
Th1Th17CM Lymphocyte Subpopulation as a Predictive Biomarker of Disease Activity in Multiple Sclerosis Patients under Dimethyl Fumarate or Fingolimod Treatment.
Mediators Inflamm
; 2019: 8147803, 2019.
Artigo
Inglês
| MEDLINE | ID: mdl-31346315
12.
Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates.
Mult Scler
; 24(14): 1843-1851, 2018 12.
Artigo
Inglês
| MEDLINE | ID: mdl-28984163
13.
Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.
Brain
; 140(9): 2426-2443, 2017 Sep 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29050389
14.
Defining secondary progressive multiple sclerosis.
Brain
; 139(Pt 9): 2395-405, 2016 09.
Artigo
Inglês
| MEDLINE | ID: mdl-27401521
15.
Cryopreserved vitamin D3-tolerogenic dendritic cells pulsed with autoantigens as a potential therapy for multiple sclerosis patients.
J Neuroinflammation
; 13(1): 113, 2016 05 20.
Artigo
Inglês
| MEDLINE | ID: mdl-27207486
16.
Baseline clinical status as a predictor of methylprednisolone response in multiple sclerosis relapses.
Mult Scler
; 22(1): 117-21, 2016 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-26540732
17.
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies.
J Neurol
; 271(1): 472-485, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-37768389
18.
Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients.
Eur J Immunol
; 42(3): 771-82, 2012 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-22488365
19.
Treatment of older patients with multiple sclerosis: Results of an International Delphi Survey.
Mult Scler J Exp Transl Clin
; 9(3): 20552173231198588, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37720692
20.
Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study.
J Clin Med
; 12(23)2023 Nov 23.
Artigo
Inglês
| MEDLINE | ID: mdl-38068295